Next Article in Journal
Enhanced Synthesis of Antioxidant Enzymes, Defense Proteins and Leghemoglobin in Rhizobium-Free Cowpea Roots after Challenging with Meloydogine incognita
Previous Article in Journal
Quantitative Proteomics of the Root of Transgenic Wheat Expressing TaBWPR-1.2 Genes in Response to Waterlogging
Article Menu

Export Article

Open AccessArticle
Proteomes 2014, 2(4), 501-526; doi:10.3390/proteomes2040501

A Systems Biology Approach to Understanding the Mechanisms of Action of an Alternative Anticancer Compound in Comparison to Cisplatin

1
Molecular Physiology Department, and the Molecular Medicine Research Group, School of Medicine, University of Western Sydney, Campbelltown, NSW 2751, Australia
2
Proteomics Core Facility, Faculty of Science, University of Technology, Sydney, NSW 2007, Australia
3
School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, NSW 2052, Australia
4
School of Science and Health, University of Western Sydney, Campbelltown, NSW 2751, Australia
*
Author to whom correspondence should be addressed.
Received: 27 August 2014 / Revised: 19 September 2014 / Accepted: 29 October 2014 / Published: 10 November 2014
View Full-Text   |   Download PDF [1014 KB, uploaded 10 November 2014]   |  

Abstract

Many clinically available anticancer compounds are designed to target DNA. This commonality of action often yields overlapping cellular response mechanisms and can thus detract from drug efficacy. New compounds are required to overcome resistance mechanisms that effectively neutralise compounds like cisplatin and those with similar chemical structures. Studies have shown that 56MESS is a novel compound which, unlike cisplatin, does not covalently bind to DNA, but is more toxic to many cell lines and active against cisplatin-resistant cells. Furthermore, a transcriptional study of 56MESS in yeast has implicated iron and copper metabolism as well as the general yeast stress response following challenge with 56MESS. Beyond this, the cytotoxicity of 56MESS remains largely uncharacterised. Here, yeast was used as a model system to facilitate a systems-level comparison between 56MESS and cisplatin. Preliminary experiments indicated that higher concentrations than seen in similar studies be used. Although a DNA interaction with 56MESS had been theorized, this work indicated that an effect on protein synthesis/ degradation was also implicated in the mechanism(s) of action of this novel anticancer compound. In contrast to cisplatin, the different mechanisms of action that are indicated for 56MESS suggest that this compound could overcome cisplatin resistance either as a stand-alone treatment or a synergistic component of therapeutics. View Full-Text
Keywords: yeast; platinum; proteomics; 2D electrophoresis yeast; platinum; proteomics; 2D electrophoresis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Wright, E.P.; Padula, M.P.; Higgins, V.J.; Aldrich-Wright, J.R.; Coorssen, J.R. A Systems Biology Approach to Understanding the Mechanisms of Action of an Alternative Anticancer Compound in Comparison to Cisplatin. Proteomes 2014, 2, 501-526.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Proteomes EISSN 2227-7382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top